The impact of 18FDG-PET/CT in modifying the treatment strategy in locally advanced or high risk breast cancer patients

被引：0
|
作者：
Valli, M. C. [1 ]
Fanti, P. [1 ]
Pittoni, P. [1 ]
Pesce, G. [1 ]
Martucci, F. [1 ]
Azinwi, N. C. [1 ]
Stelmes, J. J. [1 ]
Richetti, A. [1 ]
机构：
[1] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
来源：
STRAHLENTHERAPIE UND ONKOLOGIE | 2015年 / 191卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C09
引用
收藏
页码：84 / 84
页数：1
相关论文
共 50 条
  • [31] Impact of pretreatment second look 18FDG-PET/CT on stage and treatment changes in head and neck cancer
    Elicin, Olgun
    Vollnberg, Bernd
    Shelan, Mohamed
    Riggenbach, Elena
    Bojaxhiu, Beat
    Mathier, Etienne
    Giger, Roland
    Aebersold, Daniel M.
    Klaeser, Bernd
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 31 : 8 - 13
  • [32] THE ROLE OF 18FDG-PET/CT AND KI67 IN THE EVALUATION OF EARLY RESPONSE TO NEO-ADJUVANT CHEMOTHERAPY IN LOCALLY ADVANCED BREAST CANCER (LABC).
    Dockx, Y.
    Van den Wyngaert, T.
    Altintas, S.
    Papadimitriou, K.
    Baldewijns, M.
    Van Dam, P.
    Tjalma, W. A.
    Stroobants, S.
    Huizing, M. T.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2014, 24 (09) : 1040 - 1040
  • [33] Clinical impact of 18FDG-PET and PET/CT in the evaluation of pathologic response after treatment in oesophageal cancer's patient
    Gasparini, M. D.
    Florimonte, L.
    Valisi, E.
    Leo, R.
    Benti, R.
    Gerundini, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S178 - S178
  • [34] Role of 18FDG-PET/CT in the Staging of Large Primary Operable Breast Cancer.
    Groheux, D.
    Giacchetti, S.
    Hamy, A-S
    Vercellino, L.
    Delord, M.
    Berenger, N.
    Toubert, M-E
    Misset, J-L
    Hindie, E.
    Espie, M.
    CANCER RESEARCH, 2011, 71
  • [35] Dynamic 18FDG PET/CT and dynamic contrast enhanced MRI of locally advanced breast cancer
    O Kupik
    M Tuncel
    F Demirkazik
    M Akpinar
    K Altundag
    B Erbas
    Cancer Imaging, 14 (Suppl 1)
  • [36] Correlative in vitro and in vivo studies with 18FDG-PET in breast cancer patients.
    Molthoff, CF
    Bos, R
    Van der Hoeven, JJ
    Van der Wall, E
    Van der Groep, P
    Hoekstra, OS
    Van Diest, PJ
    Lammertsma, AA
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 26P - 26P
  • [37] Response monitoring by 18FDG-PET in locally advanced NSCLC treated with concurrent chemoradiotherapy
    Van Diessen, J. N. A.
    La Fontaine, M.
    Van den Heuvel, M.
    Vogel, W.
    Belderbos, J. S. A.
    Sonke, J. J.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S488 - S488
  • [38] PREDICTION OF OUTCOME WITH 18FDG-PET IN DEFINITIVE CHEMORADIOTHERAPY FOR LOCALLY ESOPHAGEAL CANCER
    Atsumi, K.
    Shioyama, Y.
    Ohga, S.
    Yoshitake, T.
    Nonoshita, T.
    Ohnishi, K.
    Terashimai, K.
    Abe, K.
    Katsurnasa, N.
    Hiroshi, H.
    RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S287 - S287
  • [39] Risk stratification in patients with advanced-stage breast cancer by pretreatment [18F]FDG PET/CT
    Chen, Suyun
    Ibrahim, Nuhad K.
    Yan, Yuanqing
    Wong, Stephen T.
    Wang, Hui
    Wong, Franklin C.
    CANCER, 2015, 121 (22) : 3965 - 3974
  • [40] Analysis of 18FDG-PET/CT in Patients with Gastrointestinal Neuroendocrine Neoplasm
    Yu, J.
    Yang, Z.
    Fan, Y.
    Lu, M.
    Li, J.
    NEUROENDOCRINOLOGY, 2016, 103 : 64 - 64
12345